Clinical Trials
5
Active:1
Completed:0
Trial Phases
2 Phases
Phase 3:1
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (80.0%)Phase 3
1 (20.0%)Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury
Not Applicable
Not yet recruiting
- Conditions
- Cardiac Surgery Associated - Acute Kidney InjuryAKI - Acute Kidney Injury
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT07123935
- Locations
- 🇲🇾
Institut Jantung Negara, Kuala Lumpur, Malaysia
🇲🇾Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
Not Applicable
Recruiting
- Conditions
- AKI - Acute Kidney InjuryCardiac Surgery Associated - Acute Kidney Injury
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06811805
- Locations
- 🇧🇪
Jessa Medica Center, Hasselt, Belgium
🇩🇪TUM Klinikum Deutsches Herzzentrum, Munich, Germany
🇩🇪Uniklinikum Munster, Munster, Germany
TARGET: A Study to Evaluate the Treatment of Patients With Acute Decompensated Heart Failure (ADHF) Using an Automated Fluid Management System
Not Applicable
- Conditions
- Congestive Heart Failure
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03897842
- Locations
- 🇵🇱
Military Hospital of Wroclaw, Wroclaw, Poland
Reprieve ADHF EFS IDE
Not Applicable
- Conditions
- Congestive Heart Failure
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03866551
Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
Phase 3
Active, not recruiting
- Conditions
- Contrast Induced Nephropathy
- Interventions
- Device: RenalGuard TherapyDrug: Standard Therapy
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- CardioRenal Systems, Inc.
- Target Recruit Count
- 326
- Registration Number
- NCT01456013
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Torrance Medical Center, Torrance, California, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States
News
No news found